𝔖 Bobbio Scriptorium
✦   LIBER   ✦

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

✍ Scribed by Manns, Michael; Pol, Stanislas; Jacobson, Ira M; Marcellin, Patrick; Gordon, Stuart C; Peng, Cheng-Yuan; Chang, Ting-Tsung; Everson, Gregory T; Heo, Jeong; Gerken, Guido; Yoffe, Boris; Towner, William J; Bourliere, Marc; Metivier, Sophie; Chu, Chi-Jen; Sievert, William; Bronowicki, Jean-Pierre; Thabut, Dominique; Lee, Youn-Jae; Kao, Jia-Horng; McPhee, Fiona; Kopit, Justin; Mendez, Patricia; Linaberry, Misti; Hughes, Eric; Noviello, Stephanie

Book ID
126829256
Publisher
The Lancet
Year
2014
Tongue
English
Weight
271 KB
Volume
384
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Dual therapy with the nonstructural prot
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
✍ Kazuaki Chayama; Shoichi Takahashi; Joji Toyota; Yoshiyasu Karino; Kenji Ikeda; πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 905 KB

The following corrections have since been made: ''BMS-790052'' has been replaced throughout with ''daclatasvir''; ''BMS-50032'' has been replaced throughout with ''asunaprevir''. The article has been updated online and in print.